Roche Holding’s anti-PDL1 immunotherapy MPDL3280A, or atezolizumab, has received priority review status from the FDA as a treatment for patients with PD-L1-positive metastatic or locally advanced non-small cell lung cancer whose disease progressed with platinum-containing chemotherapy. A final decision from the agency is expected by Oct. 19.
This article was originally published at the “Article” source noted above and distributed by The Tutu Project for informational purposes only.
Our team is comprised of Bob and Linda Carey, our advisors and volunteers. Without them, changing lives one smile at a time would never be possible!
